EU/3/01/050: Orphan designation for the treatment of Wilson's disease

Zinc acetate dihydrate

Table of contents


Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in October 2014 at the end of the period of market exclusivity.

On 30 July 2001, orphan designation (EU/3/01/050) was granted by the European Commission to Orphan Europe s.a.r.l., France, for zinc acetate dihydrate for the treatment of Wilson's disease.

Zinc acetate dihydrate has been authorised in the EU as Wilzin since 13 October 2004.

For a list of the administrative updates to this public summary of opinion please refer to the PDF document below.

Key facts

Active substance
Zinc acetate dihydrate
Medicine name
Intended use
Treatment of Wilson's disease
Orphan designation status
EU designation number
Date of designation
Orphan Europe SARL
Immeuble Le Wilson
70 Avenue du Général de Gaulle
F-92800 Puteaux
Tel. +33 1 4773 6458
Fax +33 1 49 00 18 00

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating